Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.69 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.57 |
| ▸ | RXRA | P19793 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8002906 | 1.00 | MAPT (0.69) | MAPTRXFP1FFAR1HSD17B10HDAC3 | |
| SCHEMBL10956007 | 1.00 | MAPT (0.69) | MAPTRXFP1FFAR1HSD17B10HDAC3 | |
| SCHEMBL4189855 | 1.00 | MAPT (0.69) | MAPTRXFP1FFAR1HSD17B10HDAC3 | |
| SCHEMBL878982 | 1.00 | MAPT (0.69) | MAPTRXFP1FFAR1HSD17B10HDAC3 | |
| SCHEMBL26313655 | 1.00 | MAPT (0.69) | MAPTRXFP1FFAR1HSD17B10HDAC3 | |
| SCHEMBL25167628 | 1.00 | MAPT (0.69) | MAPTRXFP1FFAR1HSD17B10HDAC3 | |
| SCHEMBL11295813 | 1.00 | MAPT (0.69) | MAPTRXFP1FFAR1HSD17B10HDAC3 | |
| SCHEMBL11291327 | 1.00 | MAPT (0.69) | MAPTRXFP1FFAR1HSD17B10HDAC3 | |
| SCHEMBL1066202 | 0.98 | MAPT (0.66) | MAPTRXFP1FFAR1HSD17B10HDAC3 | |
| SCHEMBL1139126 | 0.98 | MAPT (0.66) | MAPTRXFP1FFAR1HSD17B10HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190240235-A1 | LIPOBALANCED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL DELIVERY | LIPOCINE INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-20170020893-A1 | LIPOBALANCED LONG CHAIN TESTOSTERONE PRODRUGS FOR ORAL DELIVERY | LIPOCINE INC. (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170020893-A1 | LIPOBALANCED LONG CHAIN TESTOSTERONE PRODRUGS FOR ORAL DELIVERY | LIPOCINE INC. (US) | 2017-01-26 | — | — | US | disclosed |
| US-20140288039-A1 | LIPOBALANCED LONG CHAIN TESTOSTERONE PRODRUGS FOR ORAL DELIVERY | LIPOCINE INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288039-A1 | LIPOBALANCED LONG CHAIN TESTOSTERONE PRODRUGS FOR ORAL DELIVERY | LIPOCINE INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-8124778-B2 | Tricyclic inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124778-B2 | Tricyclic inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124778-B2 | Tricyclic inhibitors of fatty acid amide hydrolase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100216750-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216750-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216750-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-08-26 | — | — | US | disclosed |
| EP-2161997-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Boger, Dale L. (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008150492-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008150492-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-12-11 | — | — | WO | disclosed |
| US-7459517-B2 | Polyhydroxyalkanoate, process for preparing the same, and resin composition containing the polyhydroxyalkanoate | CANON KABUSHIKI KAISHA (JP) | 2008-12-02 | — | — | US | disclosed |
| US-20060079662-A1 | High thermal stability, charge stablity, a high charge amount, improved dispersibility and biodegradability together; for resin moldings, and binders and charge controlling agents for toners used in the electrophotography | CANON KABUSHIKI KAISHA (JP) | 2006-04-13 | — | — | US | disclosed |
| WO-2004037889-A1 | POLYHYDROXYALKANOATE, PROCESS FOR PREPARING THE SAME, AND RESIN COMPOSITION CONTAINING THE POLYHYDROXYALKANOATE | CANON KABUSHIKI KAISHA (JP) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288039-A1 | LIPOBALANCED LONG CHAIN TESTOSTERONE PRODRUGS FOR ORAL DELIVERY | SHBG, CYP17A1, CYP19A1 | MAPT 3508/4885RXFP1 2799/4885FFAR1 214/4885 |
| US-20100216750-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FADS1, FAAH, SCD | MAPT 3956/4885RXFP1 2442/4885FFAR1 30/4885 |
| US-20190240235-A1 | LIPOBALANCED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL DELIVERY | SHBG, CYP17A1, LIPE | MAPT 3511/4885RXFP1 2748/4885FFAR1 200/4885 |
| US-20170020893-A1 | LIPOBALANCED LONG CHAIN TESTOSTERONE PRODRUGS FOR ORAL DELIVERY | SHBG, CYP17A1, CYP19A1 | MAPT 3508/4885RXFP1 2799/4885FFAR1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.